echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > HRS9531 Injection, a subsidiary of Hengrui Pharmaceuticals, obtained the notification of drug clinical trial approval

    HRS9531 Injection, a subsidiary of Hengrui Pharmaceuticals, obtained the notification of drug clinical trial approval

    • Last Update: 2021-11-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On October 26, Hengrui Pharmaceuticals issued an announcement stating that its subsidiary Shengdi Pharmaceuticals received the approval and issuance of the "Drug Clinical Trial Approval Notice" for HRS9531 injection from the National Medical Products Administration, and will start clinical trials in the near future


    HRS9531 injection is an innovative drug independently developed by the company, and its indication is type 2 diabetes


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.